Annual report
4564.TEDINET S100YHRD
Period2025-04-01 → 2026-03-31
Filed2026-06-23
StandardJapan GAAP
ConsolidatedYes
Data checks20 of 20 passed
Key figures · 125
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥809m | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥750m | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Operating income | −¥810m | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | −¥798m | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | −¥846m | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥1.1bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.1bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.1bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥908m | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥813m | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥911m | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.3bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥1.1bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥2.6bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥911m | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥2.4bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥1.2bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥867m | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.5bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥2.7bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥217m | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥426m | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥2.1bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥729m | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥354m | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥855m | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥2.0bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.1bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥834m | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.1bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥834m | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥528m | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.8bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥923m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥815m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.2bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥795m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥2.1bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥63m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥279,000 | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥33m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥20m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥468m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥2.2bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥671m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥96m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.5bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-2.77 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.12 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.05 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.81 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.72 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥5.4 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2.42 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1.28 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4.04 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥9.84 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 87.8% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.0% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.2% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.5% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.6% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Employees | 46 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 47 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 54 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 60 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 67 | at 2022-03-31v | Cons. | Number of employees |
| Operating income | −¥769m | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | −¥728m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | −¥776m | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥712m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥873m | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥1.1bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥2.0bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥909m | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥814m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | −¥911m | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | −¥815m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | −¥1.0bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥1.1bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | −¥2.4bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥2.3bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥840m | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥507m | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥949m | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.1bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥111m | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥111m | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥2.1bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥729m | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥354m | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥575m | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.7bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.0bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥614m | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-2.77 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-3.12 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.74 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-5.8 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-12.94 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥5.4 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2.42 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1.28 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2.58 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥8.38 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 91.9% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.3% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.0% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.4% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.3% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 383,643,700 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 271,643,700 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 217,643,700 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 192,643,700 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 192,643,700 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 18 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 18 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 27 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 28 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 36 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 43
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥307,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥307,000 |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | −¥170m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥223m |
| Cancer Precision Medical Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥63m |
| Cancer Precision Medical Businessreportable segment | employees | at 2026-03-31 | 28 pure |
| Cancer Precision Medical Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥806m |
| Cancer Precision Medical Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥806m |
| Cancer Precision Medical Businessreportable segment | segment assets | at 2026-03-31 | ¥326m |
| Cancer Precision Medical Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | −¥56m |
| Research And Development Of Pharmaceutical Productsreportable segment | employees | at 2026-03-31 | 18 pure |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥3m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥2m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥307,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment assets | at 2026-03-31 | ¥2.2bn |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2025-04-01 → 2026-03-31 | −¥532m |
| —segment total | capex | 2025-04-01 → 2026-03-31 | ¥63m |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥809m |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥809m |
| —segment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥307,000 |
| —segment total | segment assets | at 2026-03-31 | ¥2.5bn |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | −¥587m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥294,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥294,000 |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | −¥107m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥220m |
| Cancer Precision Medical Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥279,000 |
| Cancer Precision Medical Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥747m |
| Cancer Precision Medical Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥747m |
| Cancer Precision Medical Businessreportable segment | segment assets | at 2025-03-31 | ¥470m |
| Cancer Precision Medical Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥91m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥3m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥3m |
| Research And Development Of Pharmaceutical Productsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥294,000 |
| Research And Development Of Pharmaceutical Productsreportable segment | segment assets | at 2025-03-31 | ¥792m |
| Research And Development Of Pharmaceutical Productsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥487m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥279,000 |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥750m |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥750m |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥294,000 |
| —segment total | segment assets | at 2025-03-31 | ¥1.3bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | −¥578m |
| Research And Development Of Pharmaceutical Productsreportable segment | employees | at 2026-03-31 | 18 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,149
| Item | Context | Value | Unit |
|---|---|---|---|
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E05363-000KomineYuichiMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000KomineYuichiMember | Original text (Japanese)（注）３ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000YamaneYukaMember | Original text (Japanese)監査役（常勤） | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000YamaneYukaMember | Original text (Japanese)山根 由香 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000YamaneYukaMember | 1972-10-27 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E05363-000YamaneYukaMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000YamaneYukaMember | Original text (Japanese)（注）４ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000TakagiMiyakoMember | Original text (Japanese)監査役 | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000TakagiMiyakoMember | Original text (Japanese)高木 美也子 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000TakagiMiyakoMember | 1952-01-10 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E05363-000TakagiMiyakoMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000TakagiMiyakoMember | Original text (Japanese)（注）５ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000TajimaTeruhisaMember | Original text (Japanese)監査役 | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000TajimaTeruhisaMember | Original text (Japanese)田島 照久 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000TajimaTeruhisaMember | 1971-08-04 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E05363-000TajimaTeruhisaMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E05363-000TajimaTeruhisaMember | Original text (Japanese)（注）５ | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row3Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row4Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row5Member | Text · Plus | |
| Outside directors and outside corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Audits (text) | FilingDateInstant | Text · Plus | |
| Remuneration for directors and other officers (text) | FilingDateInstant | Text · Plus | |
| Shareholdings (text) | FilingDateInstant | Text · Plus | |
| Basic policy on human resources strategy employees etc (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that financial statements have been prepared in accordance with special provision financial information | CurrentYearDuration | Original text (Japanese)なお、当社は、特例財務諸表提出会社に該当し、財務諸表等規則第127条の規定により財務諸表を作成しております。 | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Consolidated balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies for preparation of consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Number of consolidated subsidiaries and names of major consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Disclosure about fiscal years etc of consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Disclosure of accounting policies (text) | CurrentYearDuration | Text · Plus | |
| Notes new accounting standards not yet applied consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Research and development expenses included in general and administrative expenses and manufacturing cost for current period (text) | CurrentYearDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding impairment loss (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding new share subscription rights etc (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1YearDuration | Text · Plus | |
| Notes regarding issued shares and treasury shares (text) | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 20 of 20 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |